Pharmacogenomics Market: Doubling to $10.3 Billion by 2025 with 8.61% CAGR

In the rapidly evolving field of pharmacogenomics, where personalized medicine meets genomics, significant growth is expected in the coming years. In 2017, the pharmacogenomics market demonstrated its potential by reaching a substantial size of $5,312.8 million. However, this is just the beginning of an exciting journey, as projections indicate remarkable progress ahead.

By 2025, the pharmacogenomics market is anticipated to soar to new heights, with an estimated value of $10,265.5 million. This robust growth trajectory reflects a compound annual growth rate (CAGR) of 8.61% from 2018 to 2025. These figures paint a vivid picture of the expanding opportunities and immense potential within the pharmacogenomics industry.

Key Market Players

OneOme, LLC, F. Hoffmann-La Roche Ltd., Empire Genomics, LLC., Dynamic DNA Laboratories, Myriad Genetics Inc., Abbott Laboratories, OPKO Health, Inc. (GeneDx.), Illumina, Inc., Thermo Fisher Scientific, Inc., Admera Health

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.alliedmarketresearch.com/request-sample/5220

The global pharmacogenomics market is experiencing a significant growth trajectory due to several key factors. One of the primary drivers is the increase in the elderly population, which is accompanied by a higher prevalence of chronic diseases such as cancer, tuberculosis, HIV, and others. As these diseases become more prevalent, the need for personalized therapy becomes paramount, leading to a surge in the adoption of pharmacogenomics procedures by healthcare professionals.

Another important factor contributing to market growth is the growing awareness among the patient population regarding personalized therapy. Patients are becoming more informed about the potential benefits of pharmacogenomics in tailoring treatments to their specific genetic makeup. This awareness is driving demand and fostering a favorable environment for the growth of the pharmacogenomics market.

The pharmacogenomics market can be further analyzed based on different aspects, including technology, application, and end users.

By Technology:

1. Next Generation Sequencing: This technology allows for rapid and comprehensive sequencing of an individual's genetic material, enabling the identification of genetic variations that influence drug response.

2. Polymerase Chain Reaction (PCR): PCR is a widely used technique in pharmacogenomics to amplify specific DNA sequences for analysis, aiding in the detection of genetic variants related to drug metabolism and response.

3. Gel Electrophoresis: Gel electrophoresis separates DNA fragments based on their size, helping in the identification of genetic variations relevant to drug efficacy and safety.

4. Mass Spectrometry: Mass spectrometry is utilized for analyzing proteins and small molecules, aiding in the identification and quantification of drug metabolites and their interactions with genetic variations.

5. Microarray: Microarrays are tools used to study gene expression and genetic variations on a large scale, facilitating pharmacogenomic research and identifying potential biomarkers.

6. Others: This category includes emerging technologies and methodologies that contribute to the advancement of pharmacogenomics, such as digital PCR, gene expression profiling, and bioinformatics.

By Application

1. Cardiovascular Disease: Pharmacogenomics plays a crucial role in tailoring medications for cardiovascular conditions, considering genetic factors that influence drug efficacy and adverse reactions.

2. Infectious Diseases: Genetic variations impact individual responses to antiviral, antibiotic, and antifungal medications, making pharmacogenomics valuable for optimizing treatment strategies.

3. Oncology: Pharmacogenomics is particularly significant in oncology, as it helps identify genetic markers that can guide targeted therapies, predict treatment response, and manage drug-related toxicities.

4. Neurological Diseases: Genetic variations influence drug response in neurological conditions like Alzheimer's disease, Parkinson's disease, and epilepsy. Pharmacogenomics aids in personalized treatment approaches for these disorders.

5. Psychiatry: Pharmacogenomic testing can assist in selecting appropriate psychiatric medications and optimizing dosages based on an individual's genetic profile, improving treatment outcomes and minimizing adverse effects.

6. Others: This category encompasses various other therapeutic areas where pharmacogenomics is applied, such as respiratory diseases, autoimmune disorders, and rare genetic diseases.

By End User:

1. Hospitals and Clinics: Healthcare institutions, including hospitals and clinics, utilize pharmacogenomics to inform treatment decisions and provide personalized medicine to patients.

2. Research Institutions: Academic and private research institutions play a vital role in advancing pharmacogenomic knowledge and developing new technologies and applications.

3. Academic Institutes: Educational institutions and universities contribute to pharmacogenomics research, training future professionals in the field, and promoting its integration into healthcare practice.

Purchase Premium Copy of Pharmacogenomics Market Growth Report at: https://www.alliedmarketresearch.com/pharmacogenomics-market/purchase-options

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

United States
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.